Thursday, October 29, 2026

 

Mindfulness-based therapy may change brain responses to drug cues in people with opioid use disorder, Mount Sinai study finds




The Mount Sinai Hospital / Mount Sinai School of Medicine







Mindfulness-Oriented Recovery Enhancement (MORE), a behavioral therapy used alongside medication treatment, may help people with opioid use disorder respond differently to drug-related cues and natural rewards, according to a randomized clinical trial led by researchers at the Icahn School of Medicine at Mount Sinai. The findings offer insight into how MORE may reduce opioid craving and support recovery.

Published in JAMA Psychiatry, the study used brain imaging to examine how MORE affects the prefrontal cortex, which helps regulate behavior, make decisions, and evaluate rewards. After eight weeks, participants who received MORE showed changes in brain activity while regulating their responses to drug-related images. These changes were associated with greater reductions in craving. At a follow-up visit approximately four months after treatment, participants receiving MORE also had greater increases in the duration of abstinence than those receiving a comparison therapy.

“Opioid use disorder is a chronic condition that can involve persistent cravings and a risk of relapse, even among people receiving medications such as methadone or buprenorphine,” says Rita Z. Goldstein, PhD, Mount Sinai Professor in Neuroimaging of Addiction, Icahn School of Medicine at Mount Sinai, and senior author of the paper. “While these medications are established treatments, additional approaches that help people manage cravings and engage with rewarding experiences beyond drug use could further support recovery.”

“The prefrontal cortex sits at the top of the brain’s hierarchy for self-control and for assigning value to our experiences, and in addiction these functions are hijacked by drug cues at the expense of other rewards,” Dr. Goldstein continues. “Showing that two months of a behavioral treatment can begin to restore this balance tells us that prefrontal function in addiction is not fixed, and that recovery of brain function is possible. The mechanistic insights we uncovered could guide efforts to optimize this mindfulness training and to develop treatments that engage the same brain mechanisms directly.” 

MORE combines mindfulness training, cognitive reappraisal (changing how a person interprets and responds to drug-related triggers), and savoring (paying attention to and enjoying everyday positive experiences). The treatment aims to reduce the influence of drug-related cues while strengthening responses to natural rewards. Study co-author Eric L. Garland, PhD, of the University of California San Diego developed MORE.

Previous studies have found that MORE can improve clinical outcomes for people with opioid misuse or opioid use disorder. However, researchers have not fully understood the brain mechanisms behind these effects.

The trial drew on the impaired response inhibition and salience attribution (iRISA) model of addiction. This model proposes that drug cues can command disproportionate attention and reward-related responses, while the brain's ability to regulate behavior weakens. The study focused on two regions: the lateral prefrontal cortex, which helps regulate craving, and the ventromedial prefrontal cortex, which helps assign value to drug-related and other rewards.

Researchers enrolled 86 people with opioid use disorder at a long-term inpatient treatment facility managed by Samaritan Daytop Village in New York City. All participants were receiving methadone or buprenorphine. They were randomly assigned to eight weeks of MORE or psychoeducational supportive therapy, a comparison treatment matched for duration and group format. Using functional magnetic resonance imaging (fMRI) before and after treatment, researchers measured brain responses to drug-related images, natural rewards, and drug-related scenes from the film Trainspotting. According to the researchers, this was the first randomized clinical trial to use fMRI to examine how MORE or a similar mindfulness-based intervention changes brain function in addiction.

Brain imaging revealed differences between the treatment groups. When participants were asked to reinterpret drug-related images to reduce their emotional impact, the MORE group showed less drug-related activity in the lateral prefrontal cortex than the comparison group. Within the MORE group, greater changes in prefrontal responses to drug cues and increased ventromedial prefrontal activity while savoring positive food-related images were associated with larger reductions in craving.

The movie-watching task revealed another difference. Participants receiving MORE showed less synchronized activity in the medial prefrontal cortex while viewing the same drug-related scenes than those receiving the comparison therapy. These similarities in brain activity across people, called inter-subject correlations, were the basis for the movie analyses. Across all participants, larger reductions in synchronized medial prefrontal responses were associated with larger reductions in craving triggered by the scenes. The findings suggest that realistic movie scenes may complement other methods for studying responses to drug cues, particularly in detecting early recovery of bottom-up drug-biased reactivity. Importantly, MORE was studied as an addition to medication treatment, not a replacement.

“Medications for opioid use disorder save lives, but they are not designed to retrain how the brain responds to the cues that trigger craving,” says first author Yuefeng Huang, PhD, a postdoctoral fellow in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai at the time of the study, who is now starting his lab at the Institute for Human Neuroscience at Boys Town National Research Hospital in Boys Town, Nebraska. “We found that after MORE, the prefrontal regions that support effortful self-control showed less drug-biased activity when participants regulated their responses to drug cues, and the more a person’s brain shifted from drug cues toward natural rewards, the more their craving dropped. That shift may free up brain resources that drug cues had been monopolizing, so people can once again enjoy everyday non-drug rewards. It may be part of what recovery looks like in the brain.” 

Together, the findings suggest that MORE may support recovery by changing brain responses to reminders of drug use and to natural rewards. They may also help researchers refine behavioral treatments and investigate other approaches that directly influence brain activity.

The team is now studying whether transcranial direct current stimulation, a noninvasive technique that uses a weak electrical current to influence brain activity, can be combined with cognitive reappraisal training. Researchers are also testing whether real-time fMRI neurofeedback can be used to train the shared prefrontal responses observed during movie viewing.

Larger studies involving more diverse participants are needed to determine whether the findings apply in other treatment settings. The team aims to recruit more women to examine whether sex-related and hormonal factors influence treatment response. Future research could help identify which addiction treatments may work best for individual patients and when to deliver them.

The study, “Prefrontal Cortical Changes With Mindfulness-Oriented Recovery Enhancement in Opioid Use Disorder: A Randomized Clinical Trial” (doi: 10.1001/jamapsychiatry.2026.3388; ClinicalTrials.gov: NCT04112186), was supported by the National Center for Complementary and Integrative Health (grant R01AT010627), with additional support from the National Institute on Drug Abuse, National Institute of Mental Health, and National Center for Advancing Translational Sciences. 

About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population. 

The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,700 clinical residents and fellows training throughout the Health System. The Graduate School of Biomedical Sciences offers 12 degree-granting programs, conducts innovative basic and translational research, and trains more than 470 postdoctoral research fellows.

Ranked No. 9 nationwide in National Institutes of Health (NIH) grant funding, the Icahn School of Medicine at Mount Sinai is among the 90th percentile of U.S. private medical schools in Sponsored Programs Direct Expenditures per Principal Investigator, according to the Association of American Medical Colleges. More than 6,900 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.

-------------------------------------------------------

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.  

###

Research shows financial anxiety makes U.S. medical procedures feel more painful




Carnegie Mellon University





Rising out-of-pocket medical costs do more than damage a patient’s bank account. New research shows that expensive healthcare prices cause people to expect greater physical pain during medical procedures, driving many patients to skip necessary appointments altogether.

The study, “Paying for Pain: How Healthcare Costs Influence Physical Pain Predictions,” was co-authored by Helen Colby, Carnegie Mellon, Deidre Popovich, Texas Tech, Ashley Angulo, University of Oregon, and Kellilynn M. Frias, American University, and published in Psychology & Marketing. Their research reveals that financial distress involving medical procedures directly spills over into sensory expectations. When patients face higher out-of-pocket fees, they experience heightened immediate financial discomfort. That discomfort triggers broader financial anxiety, which leads the brain to anticipate significantly more physical pain from procedures ranging from simple blood draws to complex endoscopies.

Researchers discovered this emotional spillover effect across three distinct experiments. In each scenario, participants evaluated identical medical procedures with identical clinical details, varying only the out-of-pocket price. When prices increased, participants consistently predicted higher physical discomfort and were less willing to schedule appointments.

"We found that the psychological pain of paying money doesn't stay separate from our physical expectations," said Helen Colby, Assistant Teaching Professor of Marketing at The Tepper School of Business and lead author of the study. "When a medical test costs more out of pocket, people mentally brace for a more painful physical experience. Financial anxiety changes how we construct the prospect of healthcare in our minds before we ever set foot in a doctor's office.”

The findings highlight a critical vulnerability for consumers already facing tight budgets. General financial stress amplifies this reaction, making low-income or financially strained individuals the most likely to delay medical care due to cost-induced fear of pain.

"Healthcare providers and marketers need to realize that price tags carry heavy emotional weight," Colby said. "Communicating lower-cost options, offering clear payment plans, or framing preventive care as low-cost can lower financial anxiety. By reducing the pain of payment, we can decrease expected physical discomfort and encourage patients to get the medical care they need.

A new UV light-based technique reveals hidden mineral deposits that may have helped preserve 37,000-year-old drawings



American Chemical Society

A glowing clue to how ancient cave artworks survived

image: 

New analysis reveals that these cave drawings are partially covered by calcite mineral, which has kept them safe for tens of thousands of years.

view more 

Credit: Adapted from ACS Omega 2026, DOI: 10.1021/acsomega.6c05061






Tucked away inside a limestone cave in southeastern France lies some of the oldest artwork in existence. Known as Chauvet Cave, the site is so historically important — and fragile — that its location is kept secret and locked behind a huge steel door. And now, researchers reporting in ACS Omega have devised a technique to safely investigate these artworks and understand the natural varnish that has protected them for centuries. 

“We examine every piece of evidence to decode the techniques of prehistoric artists and understand how the paintings have been preserved over time.” — Philippe Walter

Somewhere around 37,000 years ago, a group of Paleolithic people entered what is now Chauvet Cave and left behind detailed artwork of local fauna, including cave bears, cave lions, bison, and horses. The drawings were sealed off by an ancient rockfall and left undiscovered until the 1990s. Several decades later, a lot can still be learned from these ancient works of art, including how the cave’s geology may have contributed to the artworks’ preservation. To study cave walls without damaging them, researchers have used UV fluorescence spectroscopy, which reveals fluorescent mineral deposits invisible to the naked eye. Philippe Walter and colleagues wanted to use the technique to noninvasively investigate these ancient drawings. Their focus was on mineral deposits that have formed atop the charcoal-based drawings and the techniques used to create the art. 

Due to the fragility of prehistoric footprints in front of the artwork, the researchers set up a portable spectrometer on a protective walkway around 8 feet (2.5 meters) away from the cave wall. A beam of UV light was shone on the wall, and the resulting fluorescence from the mineral deposits and pigments in the artworks was analyzed by the spectrometer. 

“Our methodology is much like forensic investigation: We examine every piece of evidence to decode the techniques of prehistoric artists and understand how the paintings have been preserved over time,” says Walter. 

The researchers’ analysis revealed that: 

  • Mineral-carrying water flowed over the wall’s limestone surface, leaving behind thin layers of calcite. That calcite glowed blue under a blacklight, revealing a natural varnish covering parts of the artwork.
  • Some areas displayed an orange fluorescence, which could be from hot charcoals or burning materials, like a lit torch, being rubbed against the wall to create the drawings.

These results showcase the careful interaction between humans and geology that allowed these artworks to be preserved for tens of thousands of years. Walter and team anticipate that the technique also has applications from forensic science to monitoring biofilms onboard the International Space Station — a project already underway. 

The authors acknowledge funding from the French Ministry of Culture, the French National Centre for Scientific Research (Centre National de la Recherche Scientifique), and Sorbonne University. 

One of the authors is a founder of Lumentis, a company developing imaging instruments for historical artwork analysis. 

### 

The American Chemical Society (ACS) is one of the world's largest scientific organizations and a global leader in advancing scientific knowledge. Founded in 1876, ACS' mission is to advance scientific knowledge, empower a global community, and champion scientific integrity. Guided by its vision of a world built on science, ACS brings together people, ideas, and resources to drive discovery and innovation, support the professional growth of scientists and students, and advance scientific discussion. Through its trusted publications, scientific meetings, community networks, education and career resources, and scientific information solutions, ACS helps scientists, educators, and students make a lasting impact on their communities and the world at large. Together, these efforts support ACS' commitment to improve all lives through the transforming power of chemistry. 

Registered journalists can subscribe to the ACS journalist news portal on EurekAlert! to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org. 

Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies. 

Follow us: Facebook | LinkedIn | Instagram 

 

Who uses nicotine pouches?



University of Cincinnati survey finds sharp rise in nicotine pouch use among adult tobacco users




University of Cincinnati

Dr. Ashley Merianos, professor, University of Cincinnati

image: 

Ashley Merianos, PhD, professor in the University of Cincinnati College of Education, Criminal Justice and Human Services.

view more 

Credit: Photo courtesy of the University of Cincinnati.






A national survey study conducted by the University of Cincinnati found that nicotine pouch use increased sharply in the United States between 2021 and 2024 among adult tobacco users.

Nicotine pouch usage among “ever users” — individuals who have used the product at least once — rose from 16.4% to 31.1%, while current nicotine pouch use increased from 3% to 10.2% during the study period.

The lead investigator for the study is Ashley Merianos, PhD, professor in the University of Cincinnati School of Human Services. The study used repeated cross-sectional analysis of 2021 and 2024 YouGov survey data. It included a nationally representative sample of adult tobacco users in the United States.

The study findings were published recently in the scholarly journal Addiction.

Nicotine pouches contain a powder made of nicotine, flavorings and other ingredients. A pouch is placed between the upper or lower lip and the gum. Saliva releases the nicotine, which  is absorbed through the gums and lining of the mouth. 

In 2024, use was more common among men, adults ages 21 to 45 and people currently using tobacco products, especially smokeless tobacco users. Merianos says these patterns suggest that nicotine pouches may be used alongside other forms of tobacco for some users.

Researchers say continued monitoring is needed to track nicotine pouch use, understand how pouches fit into people’s overall nicotine use and identify populations with the highest rates of use.

Other study investigators include Joshua Lambert, PhD, associate professor in the University of Cincinnati College of Nursing, and Dan Petrovitch, PhD, postdoctoral researcher at Texas Tech University. Investigators participating in the study at the National Institutes of Health include Kristen Hamilton-Moseley, PhD, Bambi Jewett, MSN, and Kelvin Choi, PhD.

“Our data show that what was once considered a niche nicotine product is becoming a mainstream product among U.S. adult tobacco users,” explains Merianos. “Nicotine pouches are often marketed as tobacco-free alternatives, but there are still important unanswered questions regarding their long-term health effects and addiction potential.”

“Our main results showed that nicotine pouch use is increasing rapidly,” adds Merianos.

Younger adults are driving much of this growth, with adults ages 21 to 45 significantly more likely to report both “ever use” and current nicotine pouch use compared with adults over 60, adds Merianos.

Current tobacco use, not surprisingly, was one of the strongest predictors of nicotine pouch use. This suggests that these products are primarily being adopted by people who are already using other tobacco products, whether cigarettes or e-cigarettes, says Merianos.

“Most interestingly, smokeless tobacco users were the most likely to use nicotine pouches, indicating overlap between traditional oral tobacco products and newer nicotine pouch products,” says Merianos. “Dual- and poly-tobacco use remain important concerns, as our study showed that many nicotine pouch users also report using other tobacco products.”

Across groups, men had a higher prevalence of “ever use” and current use of nicotine pouches. That trend was also the case with smokeless tobacco use in general, whether snus — a Swedish smokeless and spitless tobacco product — or snuff. 

Nicotine is a stimulant that can impact the developing brain, and the human brain isn’t fully developed until age 25. This is especially relevant for tobacco users ages 21–24. The group that included this age range saw a strong increase in nicotine pouch use.
“We don’t yet know the long-term health consequences, and we also don’t know the long-term addiction potential,” explains Merianos. “If a young adult who has never smoked or used smokeless tobacco starts using nicotine pouches, will they become addicted to nicotine? And will they then switch to other products? That’s what we’re trying to figure out in the long term.”

Merianos says public health officials must continue surveillance of emerging nicotine products and how they fit into the broader tobacco marketplace.

“The tobacco industry is very strategic,” says Merianos. “They are always going to have new marketing tactics and new products. Look at what happened with electronic cigarettes. Now there are these nicotine pouches, which are exploding on the market.”

Healthcare providers and other professionals across the Midwest — and across the United States — are increasingly likely to encounter patients using nicotine pouches. “The question is: Are they prepared to discuss both the knowns and unknowns surrounding these emerging products?” asked Merianos.

 

Moving amphibians and reptiles for construction rarely delivers long-term conservation success, UBC-led global review finds



Researchers found that relocating these species to make way for development often fails to help populations thrive


University of British Columbia

Desert tortoise being measured during mitigation translocation

image: 

A biologist with the Marine Corps Air Ground Combat Center measures a desert tortoise during a mitigation translocation.

view more 

Credit: Cpl Medina Ayala-Lo






Relocating amphibians and reptiles to protect them from development rarely leads to long-term conservation success, a new UBC-led global review has found. The findings highlight the importance of habitat protection rather than relying on moving animals out of harm’s way.

Researchers reviewed 313 global cases of translocation – the movement of animals from one location to another – involving frogs, snakes and other amphibians and reptiles between 2007 and 2023. The study, published in Conservation Biology, found that conservation-focused relocations intended to protect or restore species populations were more likely to achieve long-term success than those carried out to make way for development.

“Our findings raise questions about the widespread use of translocation as a way to address habitat loss caused by human activities,” said Megan Winand, lead author of the study and lab manager of the Conservation Decisions Lab at the University of British Columbia. “Our review highlights that moving these species away from a construction site does not mean they will survive in their new home or that their population will recover.”

Only 6 per cent of development-related relocations led to population growth, and none achieved the highest standard of success: establishing a population that can survive and reproduce on its own. By comparison, 19 per cent of conservation-focused relocations showed population growth or the potential for a population to survive over the long term.

When translocation falls short

Translocation is used for two main purposes: conservation, including restoring threatened or endangered populations and reintroducing species to areas where they have disappeared; and mitigation, by reducing the immediate risks animals face during construction and other development. However, the authors found that the two main approaches to translocation had markedly different outcomes. Development-related translocations had around twice the failure rate of relocations intended to support conservation.

The researchers used a standardized framework to assess outcomes for 163 amphibian and reptile species. It measured the success in stages, from the initial survival of relocated animals to the reproduction, population growth and the survival of the newly established population over time.

Planning and monitoring make a difference

When the researchers examined the factors associated with successful translocations, two practices stood out: removing threats before animals are moved and monitoring them for longer after release. Conservation-focused projects are more likely to have incorporated these steps, while development-related relocations were less consistent.

“Without adequate follow-up, we won’t know whether animals survive in their new location, reproduce or establish a population that can survive over time,” says Winand. “Relocated animals may also leave the release sites, encounter new threats or face difficult habitat conditions.”

Protecting habitat first

The researchers say the findings add to concerns about relying on translocation to offset habitat destruction. In a separate study published in 2026, researchers at UBC documented approximately 5.1 million amphibian and reptile relocations linked with development in British Columbia between 2019 and 2022, with no requirement to monitor their survival.

The authors argue that more focus should be placed on protecting and restoring habitat, rather than treating translocation as a substitute for preserving the places wildlife needs to survive.

“We need to reconsider how the relocations of amphibians and reptiles for construction are managed in B.C., across Canada and around the world,” says Winand. “When we destroy habitat for development, we risk losing the species that live there because moving them out of harm’s way rarely ensures their long-term survival. We need to prioritize protecting habitat and explore alternatives to current mitigation practices, which this review shows are often failing to achieve meaningful conservation outcomes.”

Interview languages: English (Winand)


A northern leopard frog during a conservation release

Credit

Northwest Trek Wildlife Park_Parks Tacoma